PL3177644T3 - Immunologiczne reagenty wiążące do PD-1 - Google Patents
Immunologiczne reagenty wiążące do PD-1Info
- Publication number
- PL3177644T3 PL3177644T3 PL15750136T PL15750136T PL3177644T3 PL 3177644 T3 PL3177644 T3 PL 3177644T3 PL 15750136 T PL15750136 T PL 15750136T PL 15750136 T PL15750136 T PL 15750136T PL 3177644 T3 PL3177644 T3 PL 3177644T3
- Authority
- PL
- Poland
- Prior art keywords
- binding reagents
- immunological binding
- immunological
- reagents
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C07K16/1145—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462033177P | 2014-08-05 | 2014-08-05 | |
| US201462053366P | 2014-09-22 | 2014-09-22 | |
| US201462093368P | 2014-12-17 | 2014-12-17 | |
| PCT/IB2015/055943 WO2016020856A2 (en) | 2014-08-05 | 2015-08-05 | Immunological reagents |
| EP15750136.2A EP3177644B1 (en) | 2014-08-05 | 2015-08-05 | Immunological reagents binding to pd-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3177644T3 true PL3177644T3 (pl) | 2021-06-14 |
Family
ID=53836144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15750136T PL3177644T3 (pl) | 2014-08-05 | 2015-08-05 | Immunologiczne reagenty wiążące do PD-1 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9982053B2 (enExample) |
| EP (1) | EP3177644B1 (enExample) |
| JP (1) | JP6629321B2 (enExample) |
| KR (1) | KR102357893B1 (enExample) |
| CN (1) | CN107074947B (enExample) |
| AU (1) | AU2015298356B2 (enExample) |
| CA (1) | CA2957258C (enExample) |
| DK (1) | DK3177644T3 (enExample) |
| ES (1) | ES2847311T3 (enExample) |
| PL (1) | PL3177644T3 (enExample) |
| PT (1) | PT3177644T (enExample) |
| SG (1) | SG11201700672YA (enExample) |
| WO (1) | WO2016020856A2 (enExample) |
Families Citing this family (141)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2376535T (pt) | 2008-12-09 | 2017-06-23 | Hoffmann La Roche | Anticorpos anti-pd-l1 e a sua utilização para a melhoria do funcionamento das células t |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| JP6629321B2 (ja) * | 2014-08-05 | 2020-01-15 | マブクエスト エスエーＭａｂＱｕｅｓｔ ＳＡ | 免疫学的試薬 |
| US9982052B2 (en) * | 2014-08-05 | 2018-05-29 | MabQuest, SA | Immunological reagents |
| CU24597B1 (es) | 2014-11-26 | 2022-05-11 | Xencor Inc | Anticuerpos biespecíficos heterodiméricos que se unen a cd3 y cd20 |
| EP3303394B1 (en) | 2015-05-29 | 2020-04-08 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| JP7014706B2 (ja) | 2015-07-13 | 2022-02-01 | サイトメックス セラピューティクス インコーポレイテッド | 抗ｐｄ－１抗体、活性化可能抗ｐｄ－１抗体、およびその使用方法 |
| TWI886756B (zh) | 2015-07-30 | 2025-06-11 | 美商宏觀基因股份有限公司 | Pd-1結合分子和其使用方法 |
| BR112018006237A2 (pt) | 2015-09-29 | 2018-10-09 | Celgene Corp | proteínas de ligação a pd-1 e métodos de uso das mesmas |
| EP4046655A1 (en) | 2015-11-03 | 2022-08-24 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
| MA44082A (fr) | 2015-12-14 | 2018-10-24 | Macrogenics Inc | Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation |
| ES3034233T3 (en) | 2016-01-22 | 2025-08-14 | MabQuest SA | Non-blocking pd1 specific antibodies |
| US11214617B2 (en) * | 2016-01-22 | 2022-01-04 | MabQuest SA | Immunological reagents |
| CN106008714B (zh) * | 2016-05-24 | 2019-03-15 | 瑞阳(苏州)生物科技有限公司 | 抗人pd-1人源化单克隆抗体及其应用 |
| KR102366813B1 (ko) | 2016-05-27 | 2022-02-24 | 아게누스 인코포레이티드 | 항-tim-3 항체 및 이의 사용 방법 |
| US10787518B2 (en) * | 2016-06-14 | 2020-09-29 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
| CA3036701A1 (en) | 2016-09-19 | 2018-03-22 | Celgene Corporation | Methods of treating immune disorders using pd-1 binding proteins |
| WO2018053401A1 (en) | 2016-09-19 | 2018-03-22 | Celgene Corporation | Methods of treating vitiligo using pd-1 binding proteins |
| NZ792355A (en) | 2016-10-11 | 2025-12-19 | Agenus Inc | Anti-lag-3 antibodies and methods of use thereof |
| MA49863A (fr) | 2016-11-01 | 2020-06-17 | Anaptysbio Inc | Anticorps dirigés contre la mort programmée 1 (pd -1) |
| AR110017A1 (es) * | 2016-11-02 | 2019-02-13 | Jounce Therapeutics Inc | Anticuerpos de pd-1 y usos de estos |
| BR112019011582A2 (pt) | 2016-12-07 | 2019-10-22 | Agenus Inc. | anticorpos e métodos de utilização dos mesmos |
| SG10201912560YA (en) | 2016-12-07 | 2020-02-27 | Agenus Inc | Anti-ctla-4 antibodies and methods of use thereof |
| US11591398B2 (en) * | 2017-01-06 | 2023-02-28 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death protein 1 (PD-1) |
| SG11201906192SA (en) | 2017-01-09 | 2019-08-27 | Tesaro Inc | Methods of treating cancer with anti-pd-1 antibodies |
| MA47265A (fr) | 2017-01-13 | 2019-11-20 | Agenus Inc | Récepteurs de lymphocytes t qui se lient à ny-eso-1 et méthodes d'utilisation de ces derniers |
| CN107474135B (zh) * | 2017-02-17 | 2020-08-18 | 广西医科大学 | 抗PD-1的纳米抗体PD-1/Nb20及其制备方法与应用 |
| CN110637031B (zh) | 2017-03-04 | 2024-04-16 | 湘潭腾华生物科技有限公司 | 程序性死亡蛋白1(pd-1)的重组抗体及其用途 |
| KR20190129077A (ko) | 2017-03-15 | 2019-11-19 | 팬디온 테라퓨틱스, 인코포레이티드 | 표적화된 면역관용 |
| KR20240017409A (ko) | 2017-04-13 | 2024-02-07 | 아게누스 인코포레이티드 | 항-cd137 항체 및 이의 사용 방법 |
| CN106939049B (zh) * | 2017-04-20 | 2019-10-01 | 苏州思坦维生物技术股份有限公司 | 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用 |
| DK3618863T3 (da) | 2017-05-01 | 2023-08-21 | Agenus Inc | Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf |
| CA3064435A1 (en) | 2017-05-24 | 2018-11-29 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| JP7235733B2 (ja) * | 2017-06-05 | 2023-03-08 | ヤンセン バイオテツク，インコーポレーテツド | Ｐｄ－１に特異的に結合する抗体、及び使用方法 |
| CN111278854A (zh) | 2017-09-04 | 2020-06-12 | 艾吉纳斯公司 | 与混合谱系白血病(mll)特异性磷酸肽结合的t细胞受体和其使用方法 |
| CA3074647A1 (en) | 2017-09-07 | 2019-03-14 | Augusta University Research Institute, Inc. | Antibodies to programmed cell death protein 1 |
| CN112272563A (zh) | 2017-11-08 | 2021-01-26 | Xencor股份有限公司 | 使用新颖抗pd-1序列的双特异性和单特异性抗体 |
| WO2019092451A1 (en) | 2017-11-13 | 2019-05-16 | Crescendo Biologics Limited | Single Domain Antibodies that Bind to CD137 |
| CN108218988B (zh) * | 2017-11-29 | 2019-10-11 | 广西医科大学 | 抗PD-1的纳米抗体PD-1/Nb52及其制备方法与应用 |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
| TWI708787B (zh) * | 2018-03-02 | 2020-11-01 | 美商美國禮來大藥廠 | Pd-1促效劑抗體及其用途 |
| EP3768713A2 (en) * | 2018-03-22 | 2021-01-27 | Keires AG | Antagonistic pd-1, pd-l1 and lag-3 binding proteins |
| CN112218883A (zh) | 2018-04-26 | 2021-01-12 | 艾吉纳斯公司 | 热休克蛋白结合肽组合物及其使用方法 |
| CN108840932B (zh) * | 2018-04-28 | 2022-03-29 | 中国科学院微生物研究所 | 一种pd-1特异性抗体及其抗肿瘤应用 |
| CN110404066B (zh) * | 2018-04-28 | 2022-06-17 | 齐鲁制药有限公司 | 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途 |
| KR20210030366A (ko) | 2018-06-20 | 2021-03-17 | 인사이트 코포레이션 | 항-pd-1 항체 및 이의 용도 |
| WO2020141199A1 (en) | 2019-01-03 | 2020-07-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer |
| TW202110885A (zh) | 2019-05-20 | 2021-03-16 | 美商潘迪恩治療公司 | 靶向ＭＡｄＣＡＭ之免疫耐受性 |
| US12344850B2 (en) | 2019-07-30 | 2025-07-01 | Pairwise Plants Services, Inc. | Morphogenic regulators and methods of using the same |
| US11629190B2 (en) | 2019-08-15 | 2023-04-18 | Oregon State University | Canine antibody therapeutic for treating cancer |
| KR102231974B1 (ko) * | 2019-08-23 | 2021-03-25 | 한국과학기술원 | 사람의 프로그램된 세포사멸 단백질(pd-1)에 선택적으로 결합하는 신규한 폴리펩티드 및 이의 용도 |
| US11680098B2 (en) | 2019-08-30 | 2023-06-20 | Agenus Inc. | Antibodies that specifically bind human CD96 |
| AU2020369599A1 (en) | 2019-10-23 | 2022-05-12 | Monsanto Technology Llc | Compositions and methods for RNA-templated editing in plants |
| KR20220110739A (ko) | 2019-10-30 | 2022-08-09 | 페어와이즈 플랜츠 서비시즈, 인크. | 유형 v crispr-cas 염기 편집제 및 그의 사용 방법 |
| EP4054621A4 (en) | 2019-11-05 | 2023-12-27 | Pairwise Plants Services, Inc. | COMPOSITIONS AND METHODS FOR REPLACING RNA-ENCODED DNA ALLELES |
| KR20220131895A (ko) | 2019-11-21 | 2022-09-29 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 항-pd-1/il-15 면역사이토카인을 이용하여 pd-1을 표적으로 하는 신규한 면역요법 |
| US11976278B2 (en) | 2019-12-06 | 2024-05-07 | Pairwise Plants Services, Inc. | Recruitment methods and compounds, compositions and systems for recruitment |
| CN115380111A (zh) | 2020-01-30 | 2022-11-22 | 成对植物服务股份有限公司 | 用于碱基多样化的组合物、系统和方法 |
| BR112022012417A2 (pt) | 2020-01-31 | 2022-08-30 | Pairwise Plants Services Inc | Supressão da resposta de evitação da sombra nas plantas |
| US20230063560A1 (en) | 2020-02-04 | 2023-03-02 | Pairwise Plans Services, Inc. | Thornless and/or prickleless rubus plants |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| US12134775B2 (en) | 2020-02-21 | 2024-11-05 | Pairwise Plants Services, Inc. | Resistance to soybean cyst nematode through gene editing |
| US11999946B2 (en) | 2020-03-26 | 2024-06-04 | Pairwise Plants Services, Inc. | Methods for controlling meristem size for crop improvement |
| US11882808B2 (en) | 2020-03-27 | 2024-01-30 | Pairwise Plants Services, Inc. | Methods for improving resistance to soybean rust |
| WO2021207148A1 (en) | 2020-04-06 | 2021-10-14 | Pairwise Plants Services, Inc. | Methods and compositions for increasing resistance to ear rot and stem rot disease in maize |
| EP4135512A1 (en) | 2020-04-16 | 2023-02-22 | Pairwise Plants Services, Inc. | Methods for controlling meristem size for crop improvement |
| KR20230005955A (ko) * | 2020-05-04 | 2023-01-10 | 인히브릭스, 인크. | 개 pd-1 결합 폴리펩타이드 및 이의 용도 |
| US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
| RS66193B1 (sr) | 2020-05-26 | 2024-12-31 | Boehringer Ingelheim Int | Anti-pd-1 antitela |
| BR112022024489A2 (pt) | 2020-06-02 | 2023-01-31 | Pairwise Plants Services Inc | Métodos para o controle do tamanho do meristema para melhora da cultura agrícola |
| CN115943212A (zh) | 2020-06-17 | 2023-04-07 | 成对植物服务股份有限公司 | 控制分生组织大小以改良作物的方法 |
| AU2021300169A1 (en) | 2020-06-30 | 2023-02-02 | Pairwise Plants Services, Inc. | Compositions, systems, and methods for base diversification |
| CA3192195A1 (en) | 2020-08-28 | 2022-03-03 | Pairwise Plants Services, Inc. | Engineered proteins and methods of use thereof |
| US20220145334A1 (en) | 2020-11-06 | 2022-05-12 | Pairwise Plants Services, Inc. | Compositions and methods for rna-encoded dna-replacement of alleles |
| MX2023009468A (es) | 2021-02-11 | 2024-01-31 | Pairwise Plants Services Inc | Metodos y composiciones para modificar niveles de citoquinina oxidasa en plantas. |
| US12365910B2 (en) | 2021-02-25 | 2025-07-22 | Pairwise Plants Services, Inc. | Methods and compositions for modifying root architecture in plants |
| CN113189078B (zh) * | 2021-03-04 | 2024-04-16 | 吉林大学 | 一种靶向药物的高通量筛选方法 |
| CA3212665A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| WO2022265905A2 (en) | 2021-06-14 | 2022-12-22 | Pairwise Plants Services, Inc. | Reporter constructs, compositions comprising the same, and methods of use thereof |
| WO2022266271A1 (en) | 2021-06-17 | 2022-12-22 | Pairwise Plants Services, Inc. | Modification of growth regulating factor family transcription factors in soybean |
| UY39827A (es) | 2021-06-24 | 2023-01-31 | Pairwise Plants Services Inc | Modificación de genes de ubiquitina ligasa e3 hect para mejorar los rasgos de rendimiento |
| CN117794358A (zh) | 2021-07-01 | 2024-03-29 | 成对植物服务股份有限公司 | 用于增强根系发育的方法和组合物 |
| CN113702351B (zh) * | 2021-07-14 | 2024-08-20 | 吉林大学 | 一种对天然药物产物进行筛选和垂钓的方法 |
| CN118076742A (zh) | 2021-08-12 | 2024-05-24 | 成对植物服务股份有限公司 | 修饰油菜素内酯受体基因以改善产量性状 |
| UY39902A (es) | 2021-08-17 | 2023-03-31 | Pairwise Plants Services Inc | Métodos y composiciones para modificar genes de histidina quinasa receptores de citoquinina en plant |
| MX2024002276A (es) | 2021-08-30 | 2024-03-07 | Pairwise Plants Services Inc | Modificacion de genes de peptidasa de union a ubiquitinaen plantas para mejorar rasgos de rendimiento. |
| AR126938A1 (es) | 2021-09-02 | 2023-11-29 | Pairwise Plants Services Inc | Métodos y composiciones para mejorar la arquitectura de las plantas y los rasgos de rendimiento |
| CA3232804A1 (en) | 2021-09-21 | 2023-03-30 | Pairwise Plants Services, Inc. | Methods and compositions for reducing pod shatter in canola |
| US20230266293A1 (en) | 2021-09-21 | 2023-08-24 | Pairwise Plants Services, Inc. | Color-based and/or visual methods for identifying the presence of a transgene and compositions and constructs relating to the same |
| UY39966A (es) | 2021-10-04 | 2023-04-28 | Pairwise Plants Services Inc | Métodos para mejorar la fertilidad de la flor y el rendimiento de semillas |
| CN118302434A (zh) | 2021-10-07 | 2024-07-05 | 成对植物服务股份有限公司 | 用于改善小花育性和种子产量的方法 |
| UY40060A (es) | 2021-12-09 | 2023-07-14 | Pairwise Plants Services Inc | Métodos para mejorar la fertilidad de floretes y el rendimiento de semillas |
| WO2023114750A1 (en) | 2021-12-13 | 2023-06-22 | Pairwise Plants Services, Inc. | Model editing systems and methods relating to the same |
| US20250146008A1 (en) | 2022-01-06 | 2025-05-08 | Pairwise Plants Services, Inc. | Methods and compositions for trichome removal |
| KR20240137086A (ko) | 2022-01-28 | 2024-09-19 | 조지아뮨 인코포레이티드 | Pd-1 작용제인 세포예정사 단백질 1에 대한 항체 |
| UY40132A (es) | 2022-01-31 | 2023-08-31 | Pairwise Plants Services Inc | Supresión de la respuesta de evitación de la sombra en las plantas |
| CA3253290A1 (en) | 2022-02-28 | 2023-08-31 | Pairwise Plants Services, Inc. | MODIFIED CRISPR-CAS EFFECTOR PROTEINS AND THEIR METHODS OF USE |
| WO2023168217A1 (en) | 2022-03-02 | 2023-09-07 | Pairwise Plants Services, Inc. | Modification of brassinosteroid receptor genes to improve yield traits |
| CN115015536A (zh) * | 2022-03-30 | 2022-09-06 | 邹灵龙 | 一种即时检测pd-1抗体药浓度的试纸条和试剂盒 |
| PE20250266A1 (es) | 2022-03-31 | 2025-01-29 | Pairwise Plants Services Inc | Plantas rosaceae de floracion temprana con caracteristicas mejoradas |
| WO2023196886A1 (en) | 2022-04-07 | 2023-10-12 | Pairwise Plants Services, Inc. | Methods and compositions for improving resistance to fusarium head blight |
| EP4511387A1 (en) | 2022-04-21 | 2025-02-26 | Pairwise Plants Services, Inc. | Methods and compositions for improving yield traits |
| UY40250A (es) | 2022-05-02 | 2023-11-15 | Pairwise Plants Services Inc | Métodos y composiciones para mejorar el rendimiento y la resistencia a enfermedades |
| UY40255A (es) | 2022-05-05 | 2023-11-15 | Pairwise Plants Services Inc | Métodos y composiciones para modificar la arquitectur radicular y/o mejorar los rangos de rendimient |
| UY40326A (es) | 2022-06-27 | 2023-12-29 | Pairwise Plants Services Inc | Métodos y composiciones para modificar el escape a la sombra en plantas |
| CA3259677A1 (en) | 2022-06-29 | 2024-01-04 | Pairwise Plants Services, Inc. | METHODS AND COMPOSITIONS FOR REGULATING MERISTEMUM SIZE TO IMPROVE CROP PRODUCTION |
| CN119365481A (zh) | 2022-06-29 | 2025-01-24 | 成对植物服务股份有限公司 | 用于控制分生组织大小以进行作物改良的方法和组合物 |
| WO2024030984A1 (en) | 2022-08-04 | 2024-02-08 | Pairwise Plants Services, Inc. | Methods and compositions for improving yield traits |
| AR130164A1 (es) | 2022-08-11 | 2024-11-13 | Pairwise Plants Services Inc | Métodos y composiciones para controlar el tamaño del meristema para la mejora de los cultivos |
| UY40418A (es) | 2022-09-08 | 2024-04-02 | Pairwise Plants Services Inc | Métodos y composiciones para mejorar características de rendimiento en plantas |
| US20240200102A1 (en) | 2022-12-16 | 2024-06-20 | Pairwise Plants Services, Inc. | Fusion proteins comprising an intein polypeptide and methods of use thereof |
| WO2024137911A1 (en) | 2022-12-21 | 2024-06-27 | Pairwise Plants Services, Inc. | Engineered proteins and methods of use thereof |
| US20240279673A1 (en) | 2023-02-16 | 2024-08-22 | Pairwise Plants Services, Inc. | Methods and compositions for modifying shade avoidance in plants |
| AU2024229193A1 (en) | 2023-03-01 | 2025-09-11 | Pairwise Plants Services, Inc. | Engineered proteins and methods of use thereof |
| AR132019A1 (es) | 2023-03-02 | 2025-05-21 | Pairwise Plants Services Inc | Métodos y composiciones para modificar la evitación de la sombra en plantas |
| AR132071A1 (es) | 2023-03-09 | 2025-05-21 | Pairwise Plants Services Inc | Modificación de genes de la vía de señalización de brasinoesteroide para mejorar rasgos de rendimiento en plantas |
| PE20252680A1 (es) | 2023-03-30 | 2025-11-24 | Pairwise Plants Services Inc | Metodos y composiciones para reducir las espinas o espinillas en plantas |
| WO2024216028A1 (en) | 2023-04-12 | 2024-10-17 | Agenus Inc. | Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor |
| AU2024269008A1 (en) | 2023-05-10 | 2025-11-27 | Regeneron Pharmaceuticals, Inc. | Cd20-pd1 binding molecules and methods of use thereof |
| UY40746A (es) | 2023-05-18 | 2024-12-13 | Pairwise Plants Services Inc | Métodos y composiciones para mejorar las características de rendimiento de las plantas |
| AR133164A1 (es) | 2023-07-18 | 2025-09-03 | Pairwise Plants Services Inc | Métodos y composiciones para modificar la arquitectura radicular en plantas |
| AR133310A1 (es) | 2023-07-27 | 2025-09-17 | Pairwise Plants Services Inc | Métodos y composiciones para modificar rasgos de rendimiento de las plantas |
| AR133901A1 (es) | 2023-09-21 | 2025-11-12 | Pairwise Plants Services Inc | Plantas de frambuesa negra de floración temprana con características mejoradas |
| WO2025072453A1 (en) | 2023-09-26 | 2025-04-03 | Pairwise Plants Services, Inc. | Engineered deaminases, compositions comprising the same, and methods of use thereof |
| WO2025080537A1 (en) | 2023-10-09 | 2025-04-17 | Pairwise Plants Services, Inc. | Circular permutants of cas12a |
| WO2025080600A1 (en) | 2023-10-11 | 2025-04-17 | Pairwise Plants Services, Inc. | Methods and compositions for improving crop yield traits |
| US20250207154A1 (en) | 2023-12-21 | 2025-06-26 | Pairwise Plants Services, Inc. | Compositions and methods for rna-encoded dna-replacement of alleles |
| WO2025178902A1 (en) | 2024-02-22 | 2025-08-28 | Pairwise Plants Services, Inc. | Methods and compositions for improving yield characteristics in plants |
| WO2025252857A1 (en) | 2024-06-05 | 2025-12-11 | Institut National de la Santé et de la Recherche Médicale | Il-15 muteins with ph-dependent binding for il-15ralpha |
| WO2025252855A1 (en) | 2024-06-05 | 2025-12-11 | Institut National de la Santé et de la Recherche Médicale | IL-15 MUTEINS WITH PH-DEPENDENT BINDING FOR IL-15Rbeta |
| WO2026015427A1 (en) | 2024-07-08 | 2026-01-15 | Pairwise Plants Services, Inc. | Methods and compositions for modification of protospacer adjacent motif specificity of cas12a |
| US12428636B1 (en) | 2024-07-08 | 2025-09-30 | Pairwise Plants Services, Inc. | Methods and compositions for modification of protospacer adjacent motif specificity of CAS12A |
| WO2026019870A1 (en) | 2024-07-17 | 2026-01-22 | Pairwise Plants Services, Inc. | Engineered crispr/cas12a proteins and methods of use thereof |
| US20260022365A1 (en) | 2024-07-17 | 2026-01-22 | Pairwise Plants Services, Inc. | Engineered cytidine deaminases |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0347425B1 (en) | 1987-03-02 | 1995-12-27 | Whitehead Institute For Biomedical Research | Recombinant mycobacterial vaccine |
| US5504005A (en) | 1987-03-02 | 1996-04-02 | Albert Einstein College Of Medicine Of Yeshiva University | Recombinant mycobacterial vaccine |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1990014363A1 (en) | 1989-05-19 | 1990-11-29 | Amgen Inc. | Metalloproteinase inhibitor |
| JPH05504067A (ja) | 1990-02-26 | 1993-07-01 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼイション | 大腸菌及びマイコバクテリアのためのシャトルプラスミド |
| GB9015888D0 (en) | 1990-07-19 | 1990-09-05 | Smithkline Biolog | Vectors |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| EP0587775A4 (en) | 1991-06-06 | 1994-11-02 | Medimmune Inc | INDUCTION OF THE CTL RESPONSE BY FOREIGN ANTIGENS EXPRESSED IN MYCOBACTERIES. |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| JP3454275B2 (ja) | 1992-06-05 | 2003-10-06 | 佑 本庶 | プログラムされた細胞死に関連した新規なポリペプチドおよびそれをコードするｄｎａ |
| WO1994028933A1 (en) | 1993-06-04 | 1994-12-22 | New York University | Bispecific human monoclonal antibodies specific for human immunodeficiency virus |
| JPH07291996A (ja) | 1994-03-01 | 1995-11-07 | Yuu Honshiyo | ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物 |
| ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| ATE524495T1 (de) | 2001-07-31 | 2011-09-15 | Ono Pharmaceutical Co | Pd-1-spezifische substanz |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| ES2367430T3 (es) * | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| DK1587907T3 (da) | 2003-01-07 | 2011-04-04 | Dyax Corp | Kunitz-domænebibliotek |
| ES2729974T3 (es) | 2003-01-23 | 2019-11-07 | Ono Pharmaceutical Co | Anticuerpo específico de PD-1 y CD3 humanas |
| AU2006244885B2 (en) | 2005-05-09 | 2011-03-31 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| US8652465B2 (en) | 2005-06-08 | 2014-02-18 | Emory University | Methods and compositions for the treatment of persistent infections |
| HUE030139T2 (en) | 2006-12-27 | 2017-04-28 | Univ Emory | Compositions and methods for the treatment of infections |
| CA2691357C (en) | 2007-06-18 | 2014-09-23 | N.V. Organon | Antibodies to human programmed death receptor pd-1 |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| EP2262837A4 (en) * | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| TW201007669A (en) | 2008-08-01 | 2010-02-16 | Integrated Solutions Technology Inc | A display driving device and the driving method thereof |
| JP2012501670A (ja) * | 2008-09-12 | 2012-01-26 | アイシス・イノベーション・リミテッド | Ｐｄ−１特異抗体およびその使用 |
| JP5794917B2 (ja) * | 2008-09-12 | 2015-10-14 | アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ | Ｐｄ−１特異抗体およびその使用 |
| PL2342226T3 (pl) | 2008-09-26 | 2017-01-31 | Dana-Farber Cancer Institute, Inc. | Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania |
| EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| US20130202623A1 (en) | 2010-02-16 | 2013-08-08 | Nicolas Chomont | Pd-1 modulation and uses thereof for modulating hiv replication |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| EP2545078A1 (en) | 2010-03-11 | 2013-01-16 | UCB Pharma, S.A. | Pd-1 antibody |
| US9163087B2 (en) | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
| EP2638061B1 (en) | 2010-11-11 | 2015-04-22 | The University of Hong Kong | Soluble pd-1 variants, fusion constructs, and uses thereof |
| KR102031020B1 (ko) | 2011-03-31 | 2019-10-14 | 머크 샤프 앤드 돔 코포레이션 | 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료 |
| RS57324B1 (sr) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antitela i drugi molekuli koji vezuju b7-h1 i pd-1 |
| US9090994B2 (en) | 2011-06-08 | 2015-07-28 | Nanjingjinsirui Science & Technology Biology Corp. | Antibody humanization by framework assembly |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| AU2013201121A1 (en) | 2011-09-20 | 2013-04-04 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| JP2015509592A (ja) * | 2012-02-23 | 2015-03-30 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 免疫調節治療剤を用いた処置に対する反応性の予測及びこのような処置の間のアブスコパル効果をモニターする方法 |
| WO2013169693A1 (en) | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody |
| HUE035503T2 (en) * | 2012-10-02 | 2018-05-02 | Bristol Myers Squibb Co | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| CA3078121A1 (en) | 2013-09-13 | 2015-03-19 | Beigene Switzerland Gmbh | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| US9982052B2 (en) * | 2014-08-05 | 2018-05-29 | MabQuest, SA | Immunological reagents |
| JP6629321B2 (ja) * | 2014-08-05 | 2020-01-15 | マブクエスト エスエーＭａｂＱｕｅｓｔ ＳＡ | 免疫学的試薬 |
| EP3237446B1 (en) | 2014-12-22 | 2021-05-05 | PD-1 Acquisition Group, LLC | Anti-pd-1 antibodies |
| ES3034233T3 (en) * | 2016-01-22 | 2025-08-14 | MabQuest SA | Non-blocking pd1 specific antibodies |
| US11214617B2 (en) * | 2016-01-22 | 2022-01-04 | MabQuest SA | Immunological reagents |
-
2015
- 2015-08-05 JP JP2017526774A patent/JP6629321B2/ja active Active
- 2015-08-05 ES ES15750136T patent/ES2847311T3/es active Active
- 2015-08-05 WO PCT/IB2015/055943 patent/WO2016020856A2/en not_active Ceased
- 2015-08-05 KR KR1020177004575A patent/KR102357893B1/ko active Active
- 2015-08-05 EP EP15750136.2A patent/EP3177644B1/en active Active
- 2015-08-05 CN CN201580042199.7A patent/CN107074947B/zh active Active
- 2015-08-05 SG SG11201700672YA patent/SG11201700672YA/en unknown
- 2015-08-05 PT PT157501362T patent/PT3177644T/pt unknown
- 2015-08-05 US US15/329,760 patent/US9982053B2/en active Active
- 2015-08-05 DK DK15750136.2T patent/DK3177644T3/da active
- 2015-08-05 PL PL15750136T patent/PL3177644T3/pl unknown
- 2015-08-05 CA CA2957258A patent/CA2957258C/en active Active
- 2015-08-05 AU AU2015298356A patent/AU2015298356B2/en active Active
-
2018
- 2018-05-17 US US15/981,977 patent/US11130807B2/en active Active
-
2021
- 2021-09-27 US US17/485,752 patent/US20220169733A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2957258A1 (en) | 2016-02-11 |
| EP3177644B1 (en) | 2020-10-07 |
| US20190106493A1 (en) | 2019-04-11 |
| EP3177644A2 (en) | 2017-06-14 |
| US20220169733A1 (en) | 2022-06-02 |
| US11130807B2 (en) | 2021-09-28 |
| WO2016020856A2 (en) | 2016-02-11 |
| SG11201700672YA (en) | 2017-02-27 |
| KR102357893B1 (ko) | 2022-02-04 |
| CN107074947A (zh) | 2017-08-18 |
| US9982053B2 (en) | 2018-05-29 |
| DK3177644T3 (da) | 2021-01-11 |
| US20170226210A1 (en) | 2017-08-10 |
| WO2016020856A3 (en) | 2016-03-31 |
| ES2847311T3 (es) | 2021-08-02 |
| CA2957258C (en) | 2023-11-07 |
| CN107074947B (zh) | 2021-04-09 |
| KR20170069996A (ko) | 2017-06-21 |
| JP6629321B2 (ja) | 2020-01-15 |
| PT3177644T (pt) | 2021-01-13 |
| AU2015298356B2 (en) | 2020-11-19 |
| AU2015298356A1 (en) | 2017-02-16 |
| JP2017531028A (ja) | 2017-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3177644T3 (pl) | Immunologiczne reagenty wiążące do PD-1 | |
| IL285287B1 (en) | Antibodies to tigit | |
| IL261188A (en) | Antibodies against tigit | |
| DK3334824T3 (da) | Pd-1-antistoffer | |
| IL251963A0 (en) | Anti-pd-1 antibodies | |
| HUE048667T2 (hu) | AXL-hez kötõdõ ellenanyagok | |
| DK3201230T3 (da) | Canine pd-l1-bindende pd-l1-antistoffer | |
| MA43259A (fr) | Liants ctla4 | |
| DK3126395T3 (da) | Multispecifikke antistoffer | |
| DK3556777T3 (da) | Multispecifikke antistofkonstrukter | |
| PT3101032T (pt) | Onjugado de anticorpo anti-her2-fármaco | |
| DK3164414T3 (da) | Antistoffer for IL-15 | |
| IL291164A (en) | Anti-nme antibody | |
| LT3166970T (lt) | Patobulinti a-beta protofibriles surišantys antikūnai | |
| CL2016001147A1 (es) | Anticuerpos específicos para fcrn. | |
| PT3215530T (pt) | Anticorpos de il-6 melhorados | |
| HUE047455T2 (hu) | HPA-1A elleni antitestek | |
| HUE054148T2 (hu) | Anti-ORAI1 antitest | |
| DK3233915T3 (da) | Antistoffer til il-17c | |
| FR3019174B1 (fr) | Liant sulfoalumineux belitique | |
| TH1601002627A (th) | วิธีการเตรียมฮาโลซิเลน | |
| ES1127080Y (es) | Portafotos ecologico | |
| HK1244290A1 (en) | Antibodies to tigit | |
| TH1601000040B (th) | วิธีการยับยั้งสไลม์ | |
| TH1501007491A (th) | องค์ประกอบสารยึดเกาะสำหรับงานโครงสร้าง |